Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nucleic acid group suitable for detection of SNP sites of tumor drug-related genes and application

A drug and gene technology, applied in the nucleic acid group field of tumor drug-related gene SNP site detection, can solve the problems of high failure rate, detection failure, complicated result interpretation, etc., and achieve the effect of simple result interpretation and low cost

Inactive Publication Date: 2019-04-09
GUANGZHOU KINGMED DIAGNOSTICS GRP CO LTD +1
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The original results obtained by traditional detection methods cannot be directly displayed on the instrument, and the experimenter needs to set the parameter analysis by himself, and the result interpretation is complicated
Traditional detection methods require the use of fluorescently labeled primers or ddNTPs or long-segment primers. Exposure to room temperature or light for a long time, or repeated freezing and thawing times can easily lead to detection failure, with a high failure rate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nucleic acid group suitable for detection of SNP sites of tumor drug-related genes and application
  • Nucleic acid group suitable for detection of SNP sites of tumor drug-related genes and application
  • Nucleic acid group suitable for detection of SNP sites of tumor drug-related genes and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0086] The kit for detecting SNP sites of tumor drug-related genes provided in this embodiment includes a nucleic acid set for detecting SNP sites of tumor drug-related genes. The nucleic acid set includes the following primer combination 1-primer combination 15.

[0087] Wherein, primer combination 1 includes: amplification primers shown in SEQ ID NO.1-2 and detection primers shown in SEQ ID NO.31;

[0088] Primer combination 2 includes: amplification primers shown in SEQ ID NO.3-4 and detection primers shown in SEQ ID NO.32;

[0089] Primer combination 3 includes: amplification primers shown in SEQ ID NO.5-6 and detection primers shown in SEQ ID NO.33;

[0090] Primer combination 4 includes: amplification primers shown in SEQ ID NO.7-8 and detection primers shown in SEQ ID NO.34;

[0091] Primer combination 5 includes: amplification primers shown in SEQ ID NO.9-10 and detection primers shown in SEQ ID NO.35;

[0092] Primer combination 6 includes: amplification primers sho...

Embodiment 2

[0125] Using the kit and method of Example 1, 6 samples (all from clinics, the sample type being whole blood or buccal swab) with known SNP locus genotypes were tested, and the results are shown in Table 5-7 below.

[0126] table 5

[0127]

[0128] Table 6

[0129]

[0130] Table 7

[0131]

[0132]

[0133] Among them, the known results in Table 5-7 are statistics of sample results detected by traditional methods (fragment analysis, single base extension and sanger sequencing), and the detection results on the right are the results of detection using the nucleic acid group in Example 1. The results show that the results using the nucleic acid group and detection method of Example 1 are consistent with those of the traditional method.

experiment example 1

[0135] There are many SNP sites before and after the rs1800462 site. Within 3 bases, there are 2 SNP sites, rs771921981 and rs190484211. There are 10 SNP sites within 10 bases, and within 20 bases. There are 16 SNP sites in the base range. In addition, there is a fragment deletion mutation (ra750040431) at 27 bp upstream of the rs1800462 site, which can easily lead to sample amplification failure and may also cause detection failure. In addition, there are pseudogenes in the genome, and it is very easy to amplify non-target fragments, so the general strategy in primer design is to amplify as long as possible fragments, and then detect, which will easily result in fewer single detection sites and low throughput (such as Sequencing analysis, fragment analysis); if the amplification length is reduced, the detection will easily fail. These reasons indicate that the design of various primers for the nucleic acid set of the present invention requires creative efforts.

[0136] Bas...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a nucleic acid group suitable for detection of SNP sites of tumor drug-related genes and an application, and relates to the technical field of gene polymorphism detection. Thenucleic acid group comprises one or more of primer combination 1-primer combination 15. Polymorphism of 15 SNP sites of 9 tumor drug-related genes can be detected simultaneously by the nucleic acid group, and the nucleic acid group has the characteristics of low cost, simple result interpretation, no interference among SNP sites and the like.

Description

technical field [0001] The invention relates to the technical field of gene polymorphism detection, in particular, to a nucleic acid group suitable for detection of SNP sites of genes related to tumor drugs and its application. Background technique [0002] Tumor has become a high-incidence disease in my country, and drug therapy is the main clinical means of tumor treatment at present, but there are obvious individual differences in drug efficacy and adverse reactions. The reason for the difference, in addition to pathology, physiology, gender, age, height, weight, compliance, etc., genetic factors are important factors affecting the difference in drug response. [0003] Studies have found that the curative effect of drugs used for tumor treatment is related to multiple genotypes, and the therapeutic effects of drugs are significantly different with different genotypes. In recent years, pharmacogenomics has developed rapidly, and a variety of tumor drugs have corresponding...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886C12N1/11
CPCC12Q1/6886C12Q2600/106C12Q2600/156
Inventor 徐艳艳赵薇薇朱阳进严慧胡昌明汤愿笑甘立佳于世辉
Owner GUANGZHOU KINGMED DIAGNOSTICS GRP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com